| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Dyslipidemias | 6 | 2018 | 791 | 1.60 | Why? |
| Hypolipidemic Agents | 2 | 2018 | 208 | 1.19 | Why? |
| Platelet Aggregation Inhibitors | 9 | 2019 | 1671 | 1.18 | Why? |
| Poland | 24 | 2021 | 2368 | 1.11 | Why? |
| Percutaneous Coronary Intervention | 13 | 2019 | 3646 | 1.04 | Why? |
| Cardiopulmonary Resuscitation | 6 | 2020 | 1876 | 0.97 | Why? |
| Cardiology | 10 | 2019 | 2873 | 0.88 | Why? |
| Prasugrel Hydrochloride | 3 | 2019 | 114 | 0.85 | Why? |
| Galectin 3 | 2 | 2018 | 76 | 0.83 | Why? |
| Simvastatin | 2 | 2017 | 63 | 0.82 | Why? |
| Resistin | 1 | 2018 | 16 | 0.78 | Why? |
| Carcinoma, Small Cell | 1 | 2018 | 16 | 0.72 | Why? |
| Hypertrophy, Left Ventricular | 2 | 2018 | 219 | 0.72 | Why? |
| Heart Failure | 9 | 2021 | 6638 | 0.70 | Why? |
| Carcinoma, Neuroendocrine | 1 | 2018 | 57 | 0.68 | Why? |
| Ezetimibe | 1 | 2017 | 50 | 0.68 | Why? |
| Leptin | 1 | 2018 | 141 | 0.67 | Why? |
| Mediastinal Neoplasms | 1 | 2018 | 57 | 0.66 | Why? |
| Rosuvastatin Calcium | 1 | 2017 | 89 | 0.66 | Why? |
| Hypertension | 6 | 2019 | 8895 | 0.66 | Why? |
| Acute Coronary Syndrome | 7 | 2019 | 2107 | 0.63 | Why? |
| Lipoproteins, LDL | 1 | 2017 | 115 | 0.63 | Why? |
| Periodontal Diseases | 1 | 2017 | 87 | 0.62 | Why? |
| Intraocular Pressure | 1 | 2019 | 276 | 0.61 | Why? |
| Mean Platelet Volume | 1 | 2017 | 203 | 0.60 | Why? |
| Hypercholesterolemia | 1 | 2017 | 175 | 0.58 | Why? |
| Editorial Policies | 5 | 2017 | 408 | 0.57 | Why? |
| Societies, Medical | 9 | 2019 | 6907 | 0.57 | Why? |
| Antihypertensive Agents | 2 | 2017 | 1962 | 0.56 | Why? |
| Glaucoma | 1 | 2019 | 225 | 0.56 | Why? |
| Hemorrhage | 5 | 2019 | 3013 | 0.54 | Why? |
| Vascular Stiffness | 1 | 2017 | 264 | 0.53 | Why? |
| Atrial Fibrillation | 9 | 2019 | 2320 | 0.53 | Why? |
| Sleep Apnea, Obstructive | 3 | 2017 | 668 | 0.52 | Why? |
| Out-of-Hospital Cardiac Arrest | 2 | 2020 | 1047 | 0.52 | Why? |
| Cholesterol | 2 | 2017 | 660 | 0.52 | Why? |
| Emergency Medical Services | 5 | 2020 | 3557 | 0.50 | Why? |
| Heart Arrest | 2 | 2020 | 1239 | 0.48 | Why? |
| Extracellular Vesicles | 1 | 2018 | 607 | 0.46 | Why? |
| Blood Platelets | 3 | 2018 | 1704 | 0.45 | Why? |
| Peripheral Arterial Disease | 1 | 2017 | 471 | 0.44 | Why? |
| Coronary Artery Disease | 5 | 2019 | 2570 | 0.41 | Why? |
| Heart Injuries | 1 | 2017 | 608 | 0.41 | Why? |
| Blood Pressure | 2 | 2019 | 2198 | 0.41 | Why? |
| Patient Positioning | 1 | 2020 | 1505 | 0.39 | Why? |
| Aortic Valve Stenosis | 4 | 2018 | 741 | 0.37 | Why? |
| Prone Position | 1 | 2020 | 1861 | 0.37 | Why? |
| Tumor Necrosis Factor-alpha | 1 | 2018 | 2483 | 0.36 | Why? |
| Sodium Potassium Chloride Symporter Inhibitors | 2 | 2019 | 49 | 0.36 | Why? |
| Transcatheter Aortic Valve Replacement | 4 | 2018 | 839 | 0.35 | Why? |
| Clinical Protocols | 2 | 2018 | 2734 | 0.35 | Why? |
| Cytochrome P-450 CYP2C19 | 2 | 2017 | 25 | 0.35 | Why? |
| MicroRNAs | 2 | 2018 | 1787 | 0.35 | Why? |
| Occupational Exposure | 5 | 2020 | 4742 | 0.35 | Why? |
| Myocardial Infarction | 3 | 2018 | 3361 | 0.35 | Why? |
| Furosemide | 2 | 2019 | 99 | 0.34 | Why? |
| Platelet Activation | 3 | 2018 | 660 | 0.34 | Why? |
| Cardiovascular Diseases | 8 | 2020 | 11497 | 0.33 | Why? |
| Purinergic P2Y Receptor Antagonists | 2 | 2019 | 206 | 0.33 | Why? |
| Registries | 6 | 2020 | 12327 | 0.32 | Why? |
| Drug Combinations | 1 | 2017 | 3852 | 0.32 | Why? |
| Disease Management | 3 | 2019 | 6841 | 0.30 | Why? |
| Consensus | 2 | 2018 | 6345 | 0.29 | Why? |
| Platelet Aggregation | 2 | 2017 | 318 | 0.28 | Why? |
| Adrenergic beta-Antagonists | 2 | 2018 | 465 | 0.27 | Why? |
| Anti-HIV Agents | 1 | 2017 | 2209 | 0.27 | Why? |
| Sleep | 1 | 2017 | 2695 | 0.27 | Why? |
| Ophthalmology | 1 | 2019 | 1840 | 0.27 | Why? |
| Information Dissemination | 5 | 2017 | 2986 | 0.27 | Why? |
| Infusions, Intraosseous | 2 | 2021 | 36 | 0.27 | Why? |
| Practice Guidelines as Topic | 7 | 2019 | 15421 | 0.26 | Why? |
| Humans | 94 | 2021 | 930598 | 0.26 | Why? |
| Biomarkers | 10 | 2021 | 23361 | 0.25 | Why? |
| Platelet Function Tests | 3 | 2019 | 231 | 0.25 | Why? |
| Coronary Restenosis | 2 | 2018 | 153 | 0.25 | Why? |
| Male | 54 | 2020 | 367725 | 0.24 | Why? |
| Middle Aged | 42 | 2020 | 270681 | 0.24 | Why? |
| Diabetes Mellitus, Type 2 | 3 | 2018 | 6166 | 0.24 | Why? |
| Risk Factors | 24 | 2020 | 71621 | 0.24 | Why? |
| Aged | 41 | 2020 | 215776 | 0.24 | Why? |
| Drug-Eluting Stents | 2 | 2018 | 562 | 0.23 | Why? |
| Female | 51 | 2020 | 380317 | 0.23 | Why? |
| Paclitaxel | 2 | 2018 | 124 | 0.22 | Why? |
| Drug Packaging | 1 | 2020 | 33 | 0.21 | Why? |
| Thrombosis | 3 | 2019 | 7504 | 0.21 | Why? |
| Coronary Vessels | 2 | 2018 | 914 | 0.21 | Why? |
| Galectins | 2 | 2018 | 109 | 0.21 | Why? |
| Expert Testimony | 3 | 2021 | 658 | 0.21 | Why? |
| Heart Massage | 1 | 2020 | 60 | 0.20 | Why? |
| Syringes | 1 | 2020 | 70 | 0.20 | Why? |
| Pets | 2 | 2020 | 314 | 0.20 | Why? |
| Prognosis | 12 | 2020 | 32490 | 0.20 | Why? |
| Follow-Up Studies | 8 | 2020 | 17020 | 0.20 | Why? |
| Sirolimus | 2 | 2018 | 240 | 0.20 | Why? |
| Infusions, Intravenous | 2 | 2021 | 1224 | 0.20 | Why? |
| Personal Protective Equipment | 6 | 2021 | 15978 | 0.19 | Why? |
| Peptide Fragments | 3 | 2019 | 2075 | 0.19 | Why? |
| Atherosclerosis | 2 | 2018 | 768 | 0.19 | Why? |
| Treatment Outcome | 18 | 2020 | 51732 | 0.19 | Why? |
| Prospective Studies | 13 | 2019 | 43301 | 0.19 | Why? |
| Vascular Access Devices | 1 | 2020 | 122 | 0.18 | Why? |
| Drug Substitution | 2 | 2019 | 385 | 0.18 | Why? |
| Atrial Function, Left | 1 | 2019 | 82 | 0.18 | Why? |
| Absorbable Implants | 2 | 2019 | 191 | 0.18 | Why? |
| Basal Metabolism | 1 | 2018 | 47 | 0.18 | Why? |
| Heart Failure, Systolic | 1 | 2018 | 39 | 0.18 | Why? |
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2018 | 120 | 0.18 | Why? |
| Lithuania | 1 | 2017 | 92 | 0.17 | Why? |
| Polysomnography | 2 | 2017 | 296 | 0.17 | Why? |
| Survival Rate | 4 | 2020 | 9206 | 0.17 | Why? |
| Atrial Appendage | 1 | 2019 | 120 | 0.17 | Why? |
| Erythrocyte Indices | 1 | 2019 | 207 | 0.17 | Why? |
| Antithrombins | 2 | 2019 | 353 | 0.17 | Why? |
| Anticoagulants | 5 | 2019 | 9563 | 0.17 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 4 | 2020 | 9706 | 0.17 | Why? |
| Etoposide | 1 | 2018 | 115 | 0.17 | Why? |
| Brain-Derived Neurotrophic Factor | 1 | 2018 | 133 | 0.17 | Why? |
| Heart Septal Defects, Ventricular | 1 | 2017 | 33 | 0.17 | Why? |
| Blood Proteins | 2 | 2018 | 551 | 0.17 | Why? |
| Publishing | 2 | 2017 | 990 | 0.16 | Why? |
| Hyperuricemia | 1 | 2018 | 160 | 0.16 | Why? |
| Neurotransmitter Agents | 1 | 2017 | 57 | 0.16 | Why? |
| Journalism, Medical | 1 | 2017 | 50 | 0.16 | Why? |
| Cisplatin | 1 | 2018 | 209 | 0.16 | Why? |
| Reference Standards | 1 | 2020 | 1163 | 0.16 | Why? |
| Disposable Equipment | 1 | 2020 | 332 | 0.16 | Why? |
| Tablets | 1 | 2017 | 219 | 0.16 | Why? |
| Tomography, Optical Coherence | 3 | 2018 | 1008 | 0.16 | Why? |
| Thromboembolism | 3 | 2018 | 2101 | 0.16 | Why? |
| Random Allocation | 1 | 2019 | 773 | 0.15 | Why? |
| Coronary Occlusion | 1 | 2018 | 138 | 0.15 | Why? |
| Blood Vessel Prosthesis Implantation | 1 | 2019 | 226 | 0.15 | Why? |
| Carotid Intima-Media Thickness | 1 | 2016 | 179 | 0.15 | Why? |
| Diuretics | 1 | 2017 | 326 | 0.15 | Why? |
| Gender Identity | 1 | 2018 | 262 | 0.15 | Why? |
| Inhalation Exposure | 1 | 2020 | 405 | 0.15 | Why? |
| Hungary | 1 | 2017 | 491 | 0.15 | Why? |
| Periodicals as Topic | 3 | 2017 | 1492 | 0.15 | Why? |
| Ticlopidine | 1 | 2017 | 193 | 0.15 | Why? |
| Pilot Projects | 5 | 2018 | 5182 | 0.15 | Why? |
| Microcirculation | 1 | 2020 | 447 | 0.15 | Why? |
| Intraoperative Complications | 1 | 2018 | 221 | 0.15 | Why? |
| Hypothermia, Induced | 1 | 2017 | 176 | 0.15 | Why? |
| Aspirin | 3 | 2018 | 1043 | 0.14 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2018 | 1510 | 0.14 | Why? |
| Textiles | 1 | 2020 | 458 | 0.14 | Why? |
| Anticholesteremic Agents | 1 | 2017 | 186 | 0.14 | Why? |
| Genotyping Techniques | 1 | 2017 | 360 | 0.14 | Why? |
| Risk Assessment | 9 | 2020 | 25439 | 0.14 | Why? |
| Decision Support Techniques | 2 | 2019 | 903 | 0.14 | Why? |
| Uric Acid | 1 | 2018 | 285 | 0.14 | Why? |
| Infection Control | 3 | 2020 | 23131 | 0.14 | Why? |
| Outpatients | 2 | 2018 | 3417 | 0.14 | Why? |
| Blood Pressure Monitoring, Ambulatory | 1 | 2017 | 341 | 0.14 | Why? |
| Wound Healing | 1 | 2018 | 424 | 0.14 | Why? |
| Takotsubo Cardiomyopathy | 1 | 2020 | 453 | 0.14 | Why? |
| Natriuretic Peptide, Brain | 2 | 2018 | 1215 | 0.13 | Why? |
| Stroke | 4 | 2018 | 8839 | 0.13 | Why? |
| Automobile Driving | 1 | 2017 | 222 | 0.13 | Why? |
| Time Factors | 10 | 2019 | 31397 | 0.13 | Why? |
| Occupational Health | 2 | 2020 | 3965 | 0.13 | Why? |
| Zinc | 1 | 2021 | 817 | 0.13 | Why? |
| Neovascularization, Pathologic | 1 | 2017 | 305 | 0.13 | Why? |
| Ventricular Remodeling | 1 | 2017 | 349 | 0.13 | Why? |
| C-Reactive Protein | 3 | 2018 | 7972 | 0.12 | Why? |
| Pandemics | 18 | 2021 | 389249 | 0.12 | Why? |
| Aortic Valve | 2 | 2017 | 664 | 0.12 | Why? |
| Coronary Disease | 1 | 2019 | 645 | 0.12 | Why? |
| Coronary Angiography | 3 | 2018 | 2275 | 0.12 | Why? |
| Myocardial Ischemia | 2 | 2018 | 781 | 0.12 | Why? |
| Death, Sudden, Cardiac | 1 | 2017 | 522 | 0.12 | Why? |
| Pleural Effusion | 1 | 2018 | 680 | 0.12 | Why? |
| Equipment Reuse | 1 | 2020 | 985 | 0.12 | Why? |
| Disease Progression | 4 | 2019 | 13580 | 0.12 | Why? |
| Delivery of Health Care | 1 | 2019 | 15909 | 0.12 | Why? |
| Interleukins | 1 | 2018 | 762 | 0.12 | Why? |
| Cardiovascular Agents | 1 | 2018 | 663 | 0.12 | Why? |
| Thrombelastography | 1 | 2017 | 627 | 0.12 | Why? |
| CD4 Lymphocyte Count | 1 | 2017 | 1517 | 0.12 | Why? |
| Aged, 80 and over | 16 | 2020 | 88759 | 0.11 | Why? |
| Respiratory Protective Devices | 2 | 2020 | 1637 | 0.11 | Why? |
| Pneumonia, Viral | 11 | 2020 | 243684 | 0.11 | Why? |
| Coronavirus Infections | 12 | 2020 | 253789 | 0.11 | Why? |
| Ferritins | 1 | 2020 | 2055 | 0.11 | Why? |
| ROC Curve | 3 | 2019 | 6024 | 0.11 | Why? |
| Betacoronavirus | 9 | 2020 | 204454 | 0.11 | Why? |
| Metabolic Networks and Pathways | 1 | 2013 | 285 | 0.11 | Why? |
| Overweight | 1 | 2017 | 916 | 0.11 | Why? |
| HIV Infections | 1 | 2017 | 11620 | 0.11 | Why? |
| Extracorporeal Membrane Oxygenation | 2 | 2020 | 5002 | 0.11 | Why? |
| Prevalence | 6 | 2019 | 25773 | 0.11 | Why? |
| Muscle, Skeletal | 1 | 2018 | 915 | 0.11 | Why? |
| Metformin | 1 | 2018 | 640 | 0.11 | Why? |
| Predictive Value of Tests | 4 | 2019 | 9537 | 0.10 | Why? |
| Anterior Wall Myocardial Infarction | 1 | 2010 | 32 | 0.10 | Why? |
| Hospitals, Teaching | 1 | 2018 | 1609 | 0.10 | Why? |
| Administration, Oral | 4 | 2018 | 2340 | 0.10 | Why? |
| Shock, Septic | 1 | 2020 | 1313 | 0.10 | Why? |
| Datasets as Topic | 1 | 2017 | 1404 | 0.10 | Why? |
| Anemia | 1 | 2017 | 789 | 0.10 | Why? |
| Critical Pathways | 1 | 2020 | 1587 | 0.10 | Why? |
| Zoonoses | 2 | 2020 | 3034 | 0.10 | Why? |
| Inflammation Mediators | 2 | 2020 | 2654 | 0.10 | Why? |
| Virtual Reality | 1 | 2018 | 640 | 0.10 | Why? |
| Interdisciplinary Communication | 1 | 2017 | 1425 | 0.09 | Why? |
| Masks | 3 | 2020 | 8528 | 0.09 | Why? |
| Coronary Artery Bypass, Off-Pump | 1 | 2008 | 27 | 0.09 | Why? |
| Dietary Supplements | 1 | 2021 | 2251 | 0.09 | Why? |
| Hemodynamics | 1 | 2017 | 1562 | 0.09 | Why? |
| Neointima | 2 | 2018 | 39 | 0.09 | Why? |
| Thrombectomy | 2 | 2018 | 2272 | 0.09 | Why? |
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 1645 | 0.09 | Why? |
| Gene Expression Regulation | 2 | 2018 | 4020 | 0.09 | Why? |
| Sulfonamides | 1 | 2017 | 1294 | 0.09 | Why? |
| Patient Education as Topic | 1 | 2018 | 1476 | 0.09 | Why? |
| Kidney Diseases | 1 | 2019 | 1434 | 0.09 | Why? |
| Adult | 16 | 2020 | 244371 | 0.08 | Why? |
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1573 | 0.08 | Why? |
| Clinical Trials as Topic | 2 | 2017 | 7330 | 0.08 | Why? |
| Cross-Over Studies | 2 | 2020 | 867 | 0.08 | Why? |
| Patient Compliance | 1 | 2017 | 1468 | 0.08 | Why? |
| Disease Transmission, Infectious | 2 | 2020 | 9044 | 0.08 | Why? |
| Retrospective Studies | 10 | 2021 | 105322 | 0.08 | Why? |
| Drug Therapy, Combination | 2 | 2018 | 7268 | 0.08 | Why? |
| Oxygen Inhalation Therapy | 1 | 2020 | 3629 | 0.08 | Why? |
| Single-Blind Method | 2 | 2020 | 1283 | 0.08 | Why? |
| Smartphone | 1 | 2018 | 1840 | 0.08 | Why? |
| Vitamin D | 1 | 2021 | 2904 | 0.08 | Why? |
| Dabigatran | 2 | 2018 | 204 | 0.08 | Why? |
| Angiotensin Receptor Antagonists | 2 | 2018 | 3892 | 0.07 | Why? |
| Coronary Thrombosis | 1 | 2010 | 433 | 0.07 | Why? |
| Survivors | 1 | 2017 | 2619 | 0.07 | Why? |
| Hypoglycemic Agents | 1 | 2018 | 2165 | 0.07 | Why? |
| Kidney | 1 | 2019 | 3648 | 0.07 | Why? |
| Myocarditis | 1 | 2020 | 2731 | 0.07 | Why? |
| Cardiac Surgical Procedures | 1 | 2018 | 1931 | 0.07 | Why? |
| Incidence | 4 | 2021 | 25622 | 0.07 | Why? |
| Recovery of Function | 3 | 2020 | 2461 | 0.07 | Why? |
| Rivaroxaban | 2 | 2018 | 467 | 0.07 | Why? |
| Heart Diseases | 1 | 2021 | 3503 | 0.06 | Why? |
| Resuscitation | 2 | 2020 | 638 | 0.06 | Why? |
| Point-of-Care Systems | 1 | 2017 | 2955 | 0.06 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.06 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2018 | 5277 | 0.06 | Why? |
| Virulence | 2 | 2020 | 2172 | 0.06 | Why? |
| Respiratory Tract Infections | 2 | 2020 | 6817 | 0.06 | Why? |
| Europe | 4 | 2021 | 12702 | 0.06 | Why? |
| Dogs | 2 | 2020 | 2529 | 0.06 | Why? |
| Occupational Diseases | 1 | 2017 | 2787 | 0.06 | Why? |
| Mobile Applications | 1 | 2018 | 3032 | 0.06 | Why? |
| Postoperative Period | 2 | 2018 | 651 | 0.06 | Why? |
| Clinical Decision-Making | 3 | 2020 | 3755 | 0.06 | Why? |
| ST Elevation Myocardial Infarction | 1 | 2017 | 3051 | 0.05 | Why? |
| Cause of Death | 3 | 2020 | 4823 | 0.05 | Why? |
| Animal Husbandry | 1 | 2020 | 162 | 0.05 | Why? |
| Patient Admission | 1 | 2017 | 5250 | 0.05 | Why? |
| Models, Cardiovascular | 1 | 2020 | 153 | 0.05 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2013 | 3607 | 0.05 | Why? |
| Quality of Life | 2 | 2018 | 9820 | 0.05 | Why? |
| Head Protective Devices | 1 | 2020 | 163 | 0.05 | Why? |
| Elective Surgical Procedures | 1 | 2017 | 5338 | 0.05 | Why? |
| Adenoviridae Infections | 1 | 2020 | 150 | 0.05 | Why? |
| Equipment Design | 2 | 2020 | 3095 | 0.05 | Why? |
| Hirudins | 1 | 2019 | 75 | 0.05 | Why? |
| Pleural Effusion, Malignant | 1 | 2018 | 37 | 0.05 | Why? |
| Endothelin-1 | 1 | 2018 | 69 | 0.05 | Why? |
| Internet | 1 | 2017 | 6204 | 0.05 | Why? |
| Acenocoumarol | 1 | 2018 | 22 | 0.05 | Why? |
| Viral Vaccines | 1 | 2020 | 7560 | 0.05 | Why? |
| Europe, Eastern | 1 | 2018 | 88 | 0.05 | Why? |
| Diabetes Mellitus | 2 | 2017 | 8207 | 0.05 | Why? |
| E-Selectin | 1 | 2016 | 55 | 0.04 | Why? |
| Tissue Scaffolds | 1 | 2019 | 174 | 0.04 | Why? |
| Drug Administration Schedule | 2 | 2019 | 2324 | 0.04 | Why? |
| Angina, Unstable | 1 | 2018 | 110 | 0.04 | Why? |
| Hemoglobins | 2 | 2017 | 958 | 0.04 | Why? |
| Coronavirus, Canine | 1 | 2020 | 375 | 0.04 | Why? |
| Obesity | 2 | 2016 | 7388 | 0.04 | Why? |
| Decision Trees | 1 | 2019 | 441 | 0.04 | Why? |
| Calcitonin | 1 | 2018 | 201 | 0.04 | Why? |
| Mink | 1 | 2020 | 399 | 0.04 | Why? |
| Combined Modality Therapy | 2 | 2020 | 3395 | 0.04 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2021 | 10649 | 0.04 | Why? |
| Biomedical Research | 1 | 2017 | 5270 | 0.04 | Why? |
| Patient Simulation | 1 | 2020 | 338 | 0.04 | Why? |
| Electric Countershock | 1 | 2019 | 284 | 0.04 | Why? |
| Stress, Physiological | 1 | 2020 | 378 | 0.04 | Why? |
| Vitamin K | 1 | 2018 | 263 | 0.04 | Why? |
| Species Specificity | 1 | 2020 | 1356 | 0.04 | Why? |
| Observer Variation | 1 | 2018 | 622 | 0.04 | Why? |
| Diffusion of Innovation | 1 | 2020 | 440 | 0.04 | Why? |
| Syndrome | 1 | 2021 | 1310 | 0.04 | Why? |
| American Heart Association | 1 | 2018 | 347 | 0.04 | Why? |
| Anti-Arrhythmia Agents | 1 | 2018 | 325 | 0.04 | Why? |
| Prosthesis Design | 1 | 2018 | 594 | 0.04 | Why? |
| Echocardiography, Transesophageal | 1 | 2019 | 447 | 0.04 | Why? |
| Patient Selection | 2 | 2020 | 4560 | 0.04 | Why? |
| Electrocardiography, Ambulatory | 1 | 2017 | 204 | 0.04 | Why? |
| Particle Size | 1 | 2020 | 1052 | 0.04 | Why? |
| Manikins | 1 | 2018 | 466 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.03 | Why? |
| Models, Immunological | 1 | 2020 | 727 | 0.03 | Why? |
| Catheter Ablation | 1 | 2019 | 438 | 0.03 | Why? |
| Protective Factors | 1 | 2020 | 1720 | 0.03 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.03 | Why? |
| Walk Test | 1 | 2017 | 461 | 0.03 | Why? |
| Authorship | 1 | 2017 | 240 | 0.03 | Why? |
| Aerosols | 2 | 2020 | 5393 | 0.03 | Why? |
| Cats | 1 | 2020 | 1890 | 0.03 | Why? |
| Dog Diseases | 1 | 2020 | 745 | 0.03 | Why? |
| Warfarin | 1 | 2018 | 402 | 0.03 | Why? |
| Health Personnel | 2 | 2020 | 29646 | 0.03 | Why? |
| International Cooperation | 2 | 2017 | 3436 | 0.03 | Why? |
| Preoperative Care | 2 | 2017 | 1515 | 0.03 | Why? |
| Genotype | 2 | 2017 | 4697 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| Longitudinal Studies | 2 | 2018 | 9893 | 0.03 | Why? |
| Surveys and Questionnaires | 2 | 2017 | 43792 | 0.03 | Why? |
| Infectious Disease Incubation Period | 1 | 2020 | 1033 | 0.03 | Why? |
| Bioethics | 1 | 2017 | 253 | 0.03 | Why? |
| Non-ST Elevated Myocardial Infarction | 1 | 2018 | 490 | 0.03 | Why? |
| L-Lactate Dehydrogenase | 1 | 2020 | 1995 | 0.03 | Why? |
| Echocardiography | 2 | 2017 | 3661 | 0.03 | Why? |
| Disclosure | 1 | 2017 | 423 | 0.03 | Why? |
| Vitamins | 1 | 2021 | 1208 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2019 | 11304 | 0.03 | Why? |
| Pyridones | 1 | 2017 | 738 | 0.03 | Why? |
| Morbidity | 1 | 2018 | 1426 | 0.03 | Why? |
| Netherlands | 1 | 2020 | 3533 | 0.03 | Why? |
| Disease Reservoirs | 1 | 2020 | 1672 | 0.03 | Why? |
| Lung | 1 | 2020 | 31049 | 0.03 | Why? |
| Immune System | 1 | 2020 | 1479 | 0.03 | Why? |
| Area Under Curve | 1 | 2017 | 2564 | 0.03 | Why? |
| Hospitalization | 2 | 2018 | 54280 | 0.03 | Why? |
| Cardiac Catheterization | 1 | 2017 | 882 | 0.02 | Why? |
| Cross Reactions | 1 | 2020 | 4374 | 0.02 | Why? |
| Hematocrit | 1 | 2008 | 107 | 0.02 | Why? |
| Recombinant Proteins | 1 | 2019 | 3786 | 0.02 | Why? |
| Gene Frequency | 1 | 2013 | 1210 | 0.02 | Why? |
| Health Literacy | 1 | 2018 | 1078 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2018 | 5440 | 0.02 | Why? |
| Liver Cirrhosis | 1 | 2018 | 1810 | 0.02 | Why? |
| Pyrazoles | 1 | 2017 | 1791 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Young Adult | 4 | 2019 | 93724 | 0.02 | Why? |
| Angioplasty, Balloon, Coronary | 1 | 2010 | 365 | 0.02 | Why? |
| Demography | 1 | 2013 | 1660 | 0.02 | Why? |
| Animals | 3 | 2020 | 78931 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2020 | 7220 | 0.02 | Why? |
| Severity of Illness Index | 3 | 2020 | 48226 | 0.02 | Why? |
| Drug Resistance | 1 | 2008 | 395 | 0.02 | Why? |
| Emergencies | 1 | 2020 | 4095 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2021 | 5993 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2017 | 2844 | 0.02 | Why? |
| Smoking | 1 | 2017 | 3358 | 0.02 | Why? |
| Adolescent | 3 | 2019 | 86841 | 0.02 | Why? |
| Clinical Laboratory Techniques | 2 | 2020 | 23402 | 0.02 | Why? |
| Stents | 1 | 2010 | 916 | 0.02 | Why? |
| Postoperative Care | 1 | 2008 | 755 | 0.02 | Why? |
| Body Mass Index | 1 | 2016 | 4306 | 0.02 | Why? |
| Cohort Studies | 2 | 2017 | 36005 | 0.01 | Why? |
| Chronic Disease | 1 | 2017 | 5139 | 0.01 | Why? |
| Phylogeny | 1 | 2020 | 13341 | 0.01 | Why? |
| Referral and Consultation | 1 | 2017 | 4816 | 0.01 | Why? |
| Continuous Positive Airway Pressure | 1 | 2010 | 1187 | 0.01 | Why? |
| Patient Readmission | 1 | 2010 | 1543 | 0.01 | Why? |
| Cross-Sectional Studies | 2 | 2018 | 53120 | 0.01 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.01 | Why? |
| Recurrence | 1 | 2010 | 3675 | 0.01 | Why? |
| Pulmonary Embolism | 1 | 2018 | 4775 | 0.01 | Why? |
| Pneumonia | 1 | 2018 | 5652 | 0.01 | Why? |
| Venous Thromboembolism | 1 | 2017 | 4273 | 0.01 | Why? |
| Cytokines | 1 | 2020 | 15010 | 0.01 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.01 | Why? |
| Stress, Psychological | 1 | 2020 | 10231 | 0.01 | Why? |
| Italy | 1 | 2020 | 38444 | 0.01 | Why? |
| Electrocardiography | 1 | 2010 | 3957 | 0.01 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 8811 | 0.01 | Why? |
| Global Health | 1 | 2018 | 13911 | 0.01 | Why? |
| Comorbidity | 1 | 2017 | 34796 | 0.01 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.01 | Why? |
| Child | 1 | 2020 | 70012 | 0.01 | Why? |
| United States | 1 | 2018 | 46150 | 0.01 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.01 | Why? |